MAGEA4 and serous adenocarcinoma: Previous studies that investigated MAGEA4 in ovarian cancer reported tissue expression in 57% of serous carcinomas [30] and 47% of epithelial ovarian cancer patients [31], serum levels in 22% of primary ovarian cancer patients [32] and autologous antibodies in 9% of epithelial ovarian cancer patients [31].